Christina Rizopoulos Valauri
Independent DirectorMs. Christina Rizopoulos Valauri, also known as Christina, serves as Independent Director at Health In Tech, Inc. since November 12, 2026. She is Independent Director since January 01, 2024 at Precipio, Inc. She is an Independent Director at Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.) since July 1, 2024. She is an Analyst at Cantor Fitzgerald, L.P. She serves as Venture Partner at NextGen Venture Partners. Ms. Valauri was the Managing Director and Global Director of Research at Cantor Fitzgerald & Co. from August 2013 till December 2015. Previously, she was the Managing Director and Director of U.S. Equity Research at Natixis Bleichroeder LLC, Research Division. Her background in equity securities research has provided a deep base of experience in pharmaceutical, biotech and med tech companies. She has extensive experience identifying and analyzing the commercial potential of breakthrough innovations, as well as mentoring and advising the C suite teams of private and public early stage healthcare companies through product development, regulatory, go to market strategies, potential mergers and acquisitions and IPOs. She has successfully developed and executed transformational business strategies to drive growth and enhance operating performance. She currently serves as a senior advisor with Hanover International, Inc., Astia.org and as a mentor and advisor at the Weill Cornell Medicine BioVenture eLab. Ms. Valauri is the founding partner and CEO of Sagestone Advisory, LLC. Ms. Valauri also served as the Global Director of Equity Research product for Healthcare, Energy and Commodities and served as a senior member of the broker dealer management team at the firm. She has received the Award for Excellence in Medical Education Public Affairs Association of American Medical Colleges. Earlier, Ms. Valauri was a Director of Equity Research at Gleacher & Company, Inc. since 2001. She was Director of Equity Research at Broadpoint AmTech, Inc. She was employed at CLSA Americas, LLC, Research Division. She was Managing Director and Global Director of Research at Cantor Fitzgerald & Co., Research Division. She served as a Director of Research at FAC Equities. Ms. Valauri was a Founding Partner and Director of Equity Research at Broadpoint Capital Inc., Research Division. She joined Broadpoint Capital Inc. in 2001. Ms. Valauri has extensive Wall Street experience spanning over many years and has been an Equity Research Director for nine years. She was a Director of Equity Research at two global financial institutions. She was an Analyst at Gruntal & Co, Research Division. Ms. Valauri was also an Associate Director of Equity Research at ING Barings, where she co managed the U.S. Equity Research Department and Director of U.S. Equity Research at Credit Agricole Securities (USA) Inc., Research Division. For many years, she was a Senior Equity Research Analyst focused on biomedical and biotechnology and pharmaceutical sectors in both the domestic and international equity markets. Ms. Valauri is recognized as a Wall Street Journal All Star Analyst, whereby she was the top ranked best on the Street Analyst in the biomedical and biotechnology sector. Ms. Valauri is widely quoted in major financial journals and has appeared on financially oriented television shows, including CNN, CNBC and the Wall Street Journal Report. Ms. Valauri received her B.A. degree in Biology from Reed College and MBA from Cornell University.
Positions
- Company NameValion Bio, Inc.Stock CodeVBIOPositionIndependent Director
